



**MOLEAC Pte. Ltd.**

11 Biopolis way • #09-08 Helios • 138667 Singapore

Tel + 65 64 78 94 30 • Fax + 65 64 78 94 35 • [www.moleac.net](http://www.moleac.net)

Company Regn No : 200210152D G.S.T. Regn No : 20-0210152-D

## **Moleac Announces Breakthrough Results on Neuroprotective and Neurogenerative Properties of NeuroAiD™**

**SINGAPORE, February 11, 2010 /PRNewswire-Asia/** -- The January issue of "Neuropharmacology", publishes the article entitled "Neuroprotective and neuroproliferative activities of NeuroAiD", reporting pharmacological data establishing NeuroAiD (MLC 601) protective effects on neuronal and brain injuries as well as its effectiveness in neurological functions recovery.

The French research team was lead by Prof. Michel Lazdunski, world-renowned specialist of pharmacology.

The data demonstrates NeuroAiD effects on decreasing cognitive deficits, preventing death of threatened neuronal tissues and improving functional outcomes by repairing and restoring neuronal circuits. This is fully consistent with clinical observations of NeuroAiD efficacy as a post stroke treatment.

NeuroAiD treatment increases survival rate, reduce infarct volume, prevent neuronal death and drastically decreased functional deficits in rodents' stroke models. The data also showed NeuroAiD's effectiveness in reducing stroke severity when administrated preventively.

The results show that NeuroAiD triggers the synthesis of Brain Derived Neurotrophic Factor (BDNF), which is known to promote neuroplasticity. Indeed NeuroAiD induces neurogenesis in rodent and human cells, and stimulates the development of new neuronal circuits of information.

Previous trials and clinical reports conducted in Asia have already demonstrated high levels of NeuroAiD safety and efficacy in improving stroke rehabilitation, even when taken several months after stroke onset. NeuroAiD Stroke Treatment is already available in many countries in Asia and in the Middle East for stroke survivors. New clinical assessments will be conducted in France and Europe shortly on stroke recovery.



David Picard, CEO of Moleac, said "We are extremely enthusiastic and proud to see these data published. It is a strong validation of our research of active ingredients in NeuroAiD as well as of our efforts towards continuous optimization of its formula. These results pave the way for new indications of NeuroAiD beyond stroke recovery such as prevention, cognitive impairments and dementia. It is good news for patients who are in need of treatment in this under-served therapeutic area."

---

#### **About Moleac**

<http://www.moleac.net>

Moleac is a Singapore-based biopharmaceutical company that dedicates itself in finding and developing new medicines for the unmet needs of patients worldwide.

#### **About NeuroAiD**

<http://www.neuroaid.com>

NeuroAiD is a stroke treatment to help stroke patients achieve faster and better recovery. NeuroAiD is derived from natural components, carefully selected for their efficacy and absence of side effects. It currently reaches out to patients in over 25 countries.

#### **Contact details:**

***Kasia Kaminska***

Telephone: +65 6478 9432

Email: [kasia.kaminska@moleac.net](mailto:kasia.kaminska@moleac.net)